论文部分内容阅读
目的 :探讨急性非淋巴细胞性白血病 (ANL L)患者乳腺癌耐药蛋白 (BCRP)基因表达与临床耐药的关系。方法 :应用半定量反转录—聚合酶链反应 (RT- PCR)并以 β2 微球蛋白 (β2 - MG)作内对照 ,检测了 36例 ANL L 患者及 10例非恶性血液病对照组患者 BCRP基因的表达 ,将 BCRP/β2 - MG≥ 0 .5定为 BCRP阳性。结果 :BCRP基因在急性白血病中 ,阳性表达高 ,表达水平差别较大 ,由低到高依次为 :对照组、完全缓解组、初治敏感组和临床耐药组。其中临床耐药组 BCRP基因表达水平显著高于对照组、完全缓解组 (P值分别为 <0 .0 2 5 ,P<0 .0 5 ) ;初治敏感组高于对照组 (P<0 .0 5 )。 ANL L BCRP基因表达似与 FAB分型无关 ,但与常用髓系单抗有关 (P<0 .0 5 )。结论 :BCRP基因在急性白血病中阳性表达率较高 ,BCRP基因过度表达可能导致 ANL L临床耐药 ,是 AN-L L患者预后的重要不利因素
Objective: To investigate the relationship between breast cancer resistance protein (BCRP) gene expression and clinical drug resistance in patients with acute non-lymphocytic leukemia (ANL L). Methods: 36 patients with ANL L and 10 patients with non-hematologic malignancies were detected by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and β2 microglobulin (β2-MG) BCRP gene expression, the BCRP / β2 - MG ≥ 0. 5 as BCRP positive. Results: The expression of BCRP gene in acute leukemia patients was high and the expression level differed greatly from low to high in order of control group, complete remission group, initial sensitive group and clinical drug resistance group. Among them, the expression of BCRP gene in clinical drug-resistant group was significantly higher than that in control group and complete remission group (P <0.05, P <0.05) .0 5). ANL L BCRP gene expression seems to be related to FAB typing but not to myeloma monoclonal antibody (P <0.05). Conclusion: The positive expression rate of BCRP gene in acute leukemia is high. BCRP gene overexpression may result in clinical drug resistance of ANL L, which is an important adverse prognostic factor in AN-L L patients